Search clinical trials for: Anticoagulant reversal

Total 6967 results

Octapharma

Not yet recruiting

Post Marketing Observational Study on Safety of BALFAXAR vs. KCENTRA for Reversal of Vitamin K Antagonist Induced Anticoagulation in Adults Undergoing Urgent Surgery or Invasive Procedure

Significant Bleeding Risk | Vitamin K-Dependent Coagulation Defect
Region Skane
The George Institute for Global Health, Australia

Not yet recruiting

International Care Bundle Evaluation in Cerebral Hemorrhage Research (I-CATCHER)

Stroke | Intraventricular Hemorrhage | Cerebrovascular Disease | Intracerebral Hemorrhage | Intracerebral Haemorrhage

Australia, Sweden
AstraZeneca
Parexel

Recruiting

A Study to Describe the Characteristics, Health Care Interventions and Outcomes of Patients With Major Bleedings in the Presence of Factor Xa Inhibitor Treatment (REVERXaL)

Major Bleeding

United States, Japan, Germany, United Kingdom
Alzheimer's Prevention and Reversal Project, Inc.
Four Winds Foundation

Recruiting

Precision Medicine Approach for Early Dementia & Mild Cognitive Impairment (EVANTHEA)

Mild Cognitive Impairment | Dementia, Mild

United States
St. Antonius Hospital
St. Antonius Research Fund

Recruiting

Routine Versus Selective Protamine Administration to Reduce Bleeding Complications After Transcatheter Aortic Valve Implantation (POPular ACE TAVI)

Aortic Valve Stenosis

Belgium, Netherlands
Takeda
Takeda Development Center Americas, Inc.

Recruiting

A Study of TAK-330 for Reversal of Direct Oral Factor Xa Inhibitor-induced Anticoagulation

Coagulation Disorder

United States, Spain, Belgium, France, Netherlands
Vascular Solutions LLC
Westat; United States Army Medical Materiel Development Activity

Not yet recruiting

Clinical Trial Assessing Non-Inferiority of Freeze Dried Plasma to Fresh Frozen Plasma in Reversing Warfarin

Anticoagulant Reversal

United States
Perosphere Pharmaceuticals Inc, a wholly owned...

Recruiting

Study of Ciraparantag for Reversal of Anticoagulation Induced by Edoxaban, Apixaban or Rivaroxaban in Healthy Adults

Healthy

United States
Brigham and Women's Hospital
CSL Behring

Recruiting

Assessment of Coagulation Factor Levels in Left Ventricular Device (LVAD )Patients Following Temporary Warfarin Reversal With Four Factor Prothrombin Complex Concentrate (4F-PCC) (KVAD)

Anticoagulation | Anticoagulation Reversal

United States
University of Ioannina

Completed

Heparin Reversal With Two Different Protamine Ratios After Cardiopulmonary By-pass.

Coagulation Disorder | Cardiac Surgery | CAD | Valve Heart Disease

Greece
HealthPartners Institute

Completed

Fixed Versus Variable Dosing of 4-factor Prothrombin Complex Concentrate for Emergent Warfarin Reversal (kcentra)

Hemorrhage | Acute Bleeding on Long-Term Anticoagulation Therapy | Significant Bleeding in Patients With a Coagulopathy (Prolonged Thrombin Time) | Urgent Reversal of Vitamin K Antagonist (VKA) Anticoagulation

United States
Portola Pharmaceuticals

Completed

A Study in Older Subjects to Evaluate the Safety and Ability of Andexanet Alfa to Reverse the Anticoagulation Effect of Apixaban

Bleeding

United States
Janssen Research & Development, LLC

Completed

A Study to Assess the Reversal of the Anticoagulant Effects of Milvexian by 4-Factor Prothrombin Complex Concentrate (4F-PCC) (Part 1) and Recombinant Human Factor VIIa (rFVIIa) (Part 2) in Healthy Participants

Healthy

Netherlands
University of Miami

Completed

Optimal Protamine Dosing for Heparin Reversal Following Cardiopulmonary Bypass

Coagulation; Intravascular

United States
Portola Pharmaceuticals

Completed

A Study in Older Subject to Evaluate the Safety and Ability of Andexanet Alfa to Reverse the Anticoagulation Effect of Rivaroxaban

Bleeding

United States
Octapharma

Completed

Study of Octaplex (Human Prothrombin Complex Concentrate) and Fresh Frozen Plasma in Patients Under Vitamin K Therapy Antagonist Needing Urgent Surgery or Invasive Procedures

Reversal of Anticoagulant Treatment

United States
The George Institute for Global Health, China
Takeda; Medical Research Council; Department for International Development, United... and other collaborators

Completed

The Third, Intensive Care Bundle With Blood Pressure Reduction in Acute Cerebral Hemorrhage Trial (INTERACT3)

Cardiovascular Diseases | Stroke | Central Nervous System Diseases | Hypertension | Diabetes | Hemorrhage | Intracranial Hemorrhages | Cerebral Hemorrhage | Anticoagulant-induced Bleeding | Cerebral Vascular Disorder | Brain Disorder

China
Octapharma

Completed

Study of Octaplex, a Four-factor Prothrombin Complex Concentrate (4F-PCC) and Beriplex® P/N (Kcentra) for the Reversal of Vitamin K Antagonist (VKA) Induced Anticoagulation in Patients Needing Urgent Surgery With Significant Bleeding Risk.

Significant Bleeding Risk

Russian Federation, United States, Romania, Ukraine, Belarus, Bulgaria, Georgia, Germany, Moldova, Republic of, Poland, Spain
Alexion Pharmaceuticals
Population Health Research Institute; Portola Pharmaceuticals, LLC (a wholly...

Completed

A Study in Participants With Acute Major Bleeding to Evaluate the Ability of Andexanet Alfa to Reverse the Anticoagulation Effect of Direct and Indirect Oral Anticoagulants (Extension Study)

Bleeding

United States, Belgium, Canada, France, Germany, Japan, Netherlands, Spain, United Kingdom
CSL Behring
Kaiser Permanente

Completed

An Observational Cohort Study to Investigate the Risk of Thromboembolic Events in Patients Receiving Kcentra® or Plasma to Reverse Vitamin K Antagonist (VKA) Therapy in the Setting of Acute Major Bleeding

Hemorrhage

United States
Baxalta now part of Shire

Completed

Efficacy and Safety of Prothromplex Total (Prothrombin Complex Concentrate) in Oral Anticoagulant Reversal

Prothrombin Complex Factor Deficiency

Hungary, Austria
Karolinska Institutet
Stockholm South General Hospital

Completed

Fast Reversal of Warfarin and Early Surgery in Patients With Trochanteric Hip Fracture A Case-control Study

Trochanteric Hip Fractures | Warfarin Medication | Early Surgery

Sweden
Perosphere Pharmaceuticals Inc, a wholly owned...

Completed

Phase 2 Study of Rivaroxaban Reversal by Ciraparantag as Measured by WBCT

Healthy

United States
Perosphere Pharmaceuticals Inc, a wholly owned...

Completed

Phase 2 Study of Apixaban Reversal by Ciraparantag as Measured by WBCT

Healthy

United States
Cardioangiologisches Centrum Bethanien

Withdrawn

Reversal Agent Use in Patients Treated With Direct Oral Anticoagulants or Vitamin K Antagonists (RADOA). Focus on New Antidots

Urgent Surgery | Severe Bleeding
Cardioangiologisches Centrum Bethanien
Goethe University; Ruhr University of Bochum; Technische Universität Dresden; University... and other collaborators

Completed

Reversal Agent Use in Patients Treated With Direct Oral Anticoagulants or Vitamin K Antagonists (RADOA)

Urgent Surgery | Severe Bleeding

Germany
Papworth Hospital NHS Foundation Trust
Austin Health

Completed

Algorithmic Protamine Dosing for Reversal of Heparin After Cardiopulmonary Bypass (PRODOSE)

Heart Diseases | Cardiovascular Diseases

United Kingdom
Perosphere Pharmaceuticals Inc, a wholly owned...

Completed

Effects of a Double-Blind, Single Dose of PER977 Administered Alone, and Following a Single Dose of Edoxaban (PER977-P1)

Anticoagulant Reversal | Reversal of Edoxaban Induced Anticoagulation

United States
Perosphere Pharmaceuticals Inc, a wholly owned...
Quintiles, Inc.

Completed

Study of PER977 Administered to Subjects With Steady State Edoxaban Dosing and Re-anticoagulation With Edoxaban

Anticoagulation Reversal

United States
Perosphere Pharmaceuticals Inc, a wholly owned...

Completed

Evaluation of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic Effects of PER977 Following Heparin

Healthy

United States
Perosphere Pharmaceuticals Inc, a wholly owned...

Completed

PK and PD of Single, Escalating Doses of PER977 Following Enoxaparin (PER977)

Healthy

United States
Boehringer Ingelheim

Completed

Reversal Dabigatran Anticoagulant Effect With Idarucizumab

Hemorrhage

Russian Federation
Boehringer Ingelheim

Completed

Medical Need of OAC Reversal

Atrial Fibrillation

Japan
University of Michigan

Completed

Use of Protamine for Heparin Reversal After Catheter Ablation of Atrial Fibrillation

Atrial Fibrillation | Catheter Ablation

United States
Hospital Quality Foundation
Janssen Scientific Affairs, LLC; Boehringer Ingelheim; Daiichi Sankyo, Inc.; CSL... and other collaborators

Unknown

Safety of Oral Anticoagulants Registry (SOAR)

Blood Coagulation

United States
Ziekenhuis Oost-Limburg

Completed

The CIRE Study (CItrate REcirculation Study) (CIRE)

Acute Kidney Injury

Belgium
Boehringer Ingelheim

Completed

Reversal of Dabigatran Anticoagulant Effect With Idarucizumab

Hemorrhage

United States, Spain, United Kingdom, Norway, Taiwan, Israel, Belgium, Australia, Sweden, Singapore, Germany, Italy, New Zealand, Austria, Japan, Canada, Czechia, Portugal, Netherlands, Korea, Republic of, France, Poland, Colombia, Hong... and more
University Medical Center Groningen
Boehringer Ingelheim; CSL Behring

Unknown

Reversal of Dabigatran With Prothrombin Complex Concentrate

Drug Action Reversal

Netherlands
Aalborg University Hospital
Medtronic

Withdrawn

Interruptions in the Coagulationsystem in Relation With Cardiac Surgery - A Study Comparing Two Heparinization Strategies During On-pump Cardiac Surgery

Cardiac Surgery

Denmark
CSL Behring

Completed

An Open-label, Randomized, Multicenter Phase IIIb Study to Assess the Efficacy, Safety and Tolerance of BERIPLEX® P/N (Kcentra) Compared With Plasma for Rapid Reversal of Coagulopathy Induced by Vitamin K Antagonists in Subjects Requiring an Urgent Surgical Procedure (BE1116_3003)

Reversal of Coagulopathy

United States, Belarus, Bulgaria, Lebanon, Romania, Russian Federation
CSL Behring

Completed

Efficacy and Safety Study of BERIPLEX® P/N (Kcentra) Compared With Plasma in Patients With Acute Major Bleeding Caused by Anticoagulant Therapy

Blood Coagulation Disorders | Acute Major Bleeding

United States, Belarus, Bulgaria, Romania, Russian Federation, Ukraine
Regado Biosciences, Inc.

Completed

Feasibility and Safety Study Comparing REG1 Anticoagulation System With Unfractionated Heparin in Elective PCI (REVERSAL-PCI)

Coronary Artery Disease

United States, Argentina
R.P.Herrmann

Completed

Assays for and Reversal of New Anticoagulants

Atrial Fibrillation | Osteoarthritis of the Hip | Osteoarthritis of the Knee

Australia
PolyMedix, Inc.

Terminated

Reversal of Heparin in Patients Undergoing Percutaneous Coronary Intervention (PCI)

Percutaneous Coronary Intervention | Coronary Artery Disease (CAD) | Angioplasty

United States
Gines Escolar
Ministry of Health, Spain

Unknown

Reversal of the Antithrombotic Action of New Oral Anticoagulants (REVANT)

Hemorrhage | Thrombosis | Anticoagulant-induced Bleeding | Anticoagulant Overdosage

Spain
The Medicines Company

Completed

Comparing Angiomax to Heparin With Protamine Reversal in Patients OPCAB (OPCAB)

Cardiac Surgery | Coronary Artery Bypass Surgery

United States
CSL Behring

Completed

Prothrombin Complex Concentrate for Anticoagulant Reversal

Acquired Coagulation Factor Deficiency

Austria, Germany, Hungary, Israel, Lithuania, Netherlands, Poland, Switzerland
Fondation Ophtalmologique Adolphe de Rothschild

Not yet recruiting

Glenzocimab in Anterior Stroke With Large Ischemic Core Eligible for Endovascular Therapy (GALICE)

Acute Ischemic Stroke
Beijing Tongren Hospital
The First Affiliated Hospital with Nanjing Medical University

Not yet recruiting

Efficacy and Safety of Sugammadex in Thoracoscopy Thymectomy for Chinese Adults With Myasthenia Gravis

Reversal of Neuromuscular Blockade

China
Ruijin Hospital

Not yet recruiting

Effect of Oxycodone on Anxiety State in Painless Abortion

Abortion Complication

Search clinical trials for: Anticoagulant reversal

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Moldova

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations